TECH vs. QGEN, RGEN, EXEL, PCVX, RVMD, NBIX, IBRX, HALO, CRSP, and KRYS
Should you be buying Bio-Techne stock or one of its competitors? The main competitors of Bio-Techne include Qiagen (QGEN), Repligen (RGEN), Exelixis (EXEL), Vaxcyte (PCVX), Revolution Medicines (RVMD), Neurocrine Biosciences (NBIX), ImmunityBio (IBRX), Halozyme Therapeutics (HALO), CRISPR Therapeutics (CRSP), and Krystal Biotech (KRYS). These companies are all part of the "biological products, except diagnostic" industry.
Bio-Techne (NASDAQ:TECH) and Qiagen (NYSE:QGEN) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, media sentiment, community ranking, dividends and earnings.
Bio-Techne presently has a consensus target price of $80.50, indicating a potential upside of 5.84%. Qiagen has a consensus target price of $50.95, indicating a potential upside of 19.65%. Given Qiagen's higher probable upside, analysts clearly believe Qiagen is more favorable than Bio-Techne.
Qiagen has higher revenue and earnings than Bio-Techne. Qiagen is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.
Bio-Techne has a beta of 1.23, meaning that its stock price is 23% more volatile than the S&P 500. Comparatively, Qiagen has a beta of 0.42, meaning that its stock price is 58% less volatile than the S&P 500.
In the previous week, Qiagen had 6 more articles in the media than Bio-Techne. MarketBeat recorded 35 mentions for Qiagen and 29 mentions for Bio-Techne. Bio-Techne's average media sentiment score of 0.63 beat Qiagen's score of 0.41 indicating that Bio-Techne is being referred to more favorably in the media.
99.0% of Bio-Techne shares are owned by institutional investors. Comparatively, 70.0% of Qiagen shares are owned by institutional investors. 4.1% of Bio-Techne shares are owned by insiders. Comparatively, 9.0% of Qiagen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Bio-Techne has a net margin of 17.59% compared to Qiagen's net margin of 17.38%. Bio-Techne's return on equity of 13.60% beat Qiagen's return on equity.
Bio-Techne received 143 more outperform votes than Qiagen when rated by MarketBeat users. Likewise, 62.48% of users gave Bio-Techne an outperform vote while only 60.79% of users gave Qiagen an outperform vote.
Summary
Bio-Techne beats Qiagen on 12 of the 18 factors compared between the two stocks.
Get Bio-Techne News Delivered to You Automatically
Sign up to receive the latest news and ratings for TECH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TECH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bio-Techne Competitors List
Related Companies and Tools
